Results 31 to 40 of about 256,231 (309)

Targeting nitrative stress for attenuating cisplatin-induced downregulation of cochlear LIM domain only 4 and ototoxicity

Redox Biology, 2016
Cisplatin-induced ototoxicity remains a primary dose-limiting adverse effect of this highly effective anticancer drug. The clinical utility of cisplatin could be enhanced if the signaling pathways that regulate the toxic side-effects are delineated.
Samson Jamesdaniel, Rajamani Rathinam, William L. Neumann   +2 more
doaj   +1 more source

Targeting HNRNPU to overcome cisplatin resistance in bladder cancer

Molecular Cancer, 2022
Purpose The overall response of cisplatin-based chemotherapy in bladder urothelial carcinoma (BUC) remains unsatisfactory due to the complex pathological subtypes, genomic difference, and drug resistance.
Zhen-duo Shi, Lin Hao, Xiao-xiao Han, Zhuo-Xun Wu, Kun Pang, Yang Dong, Jia-xin Qin, Guang-yue Wang, Xuan-ming Zhang, Tian Xia, Qing Liang, Yan Zhao, Rui Li, Shao-qi Zhang, Jun-hao Zhang, Jian-gang Chen, Gong-cheng Wang, Zhe-Sheng Chen, Cong-hui Han   +18 more
doaj   +1 more source

PERBANDINGAN KEJADIAN LEUKOPENIA DAN TROMBOSITOPENIA PADA PENDERTIA KARSINOMA NASOFARING YANG MENDAPATKAN KEMOTERAPI PACLITAXEL CISPLATIN DAN CISPLATIN 5-FLUOROURACIL (5-FU)

Jurnal Kedokteran Diponegoro, 2019
Latar Belakang : Karsinoma Nasofaring (KNF) merupakan karsinoma yang muncul pada daerah nasofaring. Kemoterapi adalah segolongan obat-obatan yang dapat menghambat pertumbuhan kanker atau bahkan membunuh sel kanker.
Nadya Tara Audina, Willy Yusmawan, Zulfikar Naftali, Suprihati Suprihati   +3 more
doaj   +1 more source

MutS homologue hMSH5: role in cisplatin-induced DNA damage response

Molecular Cancer, 2012
Background Cisplatin (cis-diamminedichloroplatinum (II), CDDP) and its analogues constitute an important class of anticancer drugs in the treatment of various malignancies; however, its effectiveness is frequently affected by mutations in genes involved ...
Tompkins Joshua D, Wu Xiling, Her Chengtao   +2 more
doaj   +1 more source

Interactions of DNA with a new Platinum(IV) Azide Dipyridine complex activated by UVA and visible light : relationship to toxicity in tumor cells [PDF]

, 2012
The Pt IV diazido complex trans,trans,trans-[Pt(N 3) 2(OH) 2(pyridine) 2] (1) is unreactive in the dark but is cytotoxic when photoactivated by UVA and visible light.
Sadler, P. J., Jitka Pracharova, Pracharova, Jitka, Kasparkova, Jana, Jana Stepankova, Farrer, Nicola J., Brabec, V. (Viktor), Lenka Zerzankova, Nicola J. Farrer, Peter J. Sadler, Jana Kasparkova, Zerzankova, Lenka, Novakova, Olga, Stepankova, Jana, Viktor Brabec, Olga Novakova   +15 more
core   +1 more source

Use of top-down and bottom-up fourier transform ion cyclotron resonance mass spectrometry for mapping calmodulin sites modified by platinum anticancer drugs [PDF]

, 2011
Calmodulin (CaM) is a highly conserved, ubiquitous, calcium-binding protein; it binds to and regulates many different protein targets, thereby functioning as a calcium sensor and signal transducer.
Lin, Tzu-Yung, Sadler, P. J., Steve L. Van Orden, Yulin Qi, Qi, Yulin, Yao Zhao, Peter B. O’Connor, Peter J. Sadler, Pizarro, Ana M., Ana M. Pizarro, Barrow, Mark P., O’Connor, Peter B., Huilin Li, Tzu-Yung Lin, Van Orden, Steve L., Zhao, Yao, (Researcher in chemistry), Mark P. Barrow, Li, Huilin   +17 more
core   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

Molecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat, Aslihan Kucuk, Omer Erdogan, Samed Ozer, Bensu Kozan, Tugba Cuceli, Erkan Gumus, Evrim Cevik, Ozge Cevik   +8 more
wiley   +1 more source

Cisplatin Nephrotoxicity

American Journal of Kidney Diseases, 1986
Cis-dichlorodiammine platinum (II), or cisplatin, has emerged as a principal chemotherapeutic agent in the treatment of otherwise resistant solid tumors and is currently among the most widely used agents in the chemotherapy of cancer. The chief limit to its greater efficacy is its nephrotoxicity, which has made it necessary both to lower its dosage and
R, Safirstein, J, Winston, M, Goldstein, D, Moel, S, Dikman, J, Guttenplan   +5 more
openaire   +2 more sources

ULTRASTRUCTURAL STUDY ON EFFECTS OF CISPLATIN ON VX2 CARCINOMA CELLS

, 1990
The effects of intraarterial chemotherapy with cisplatin on rabbit VX2 carcinoma transplanted to the hind legs of animals were studied. Following intraarterial (IA) or intravenous (IV) administration of cisplatin (2.5 mg/kg), changes in the tumor cells ...
Kuo, Jeng HSIEH
core   +1 more source

Dimethyl fumarate combined with cisplatin at subcytotoxic doses sensitizes cervical cancer toward ferroptosis and apoptosis through GSH restriction and p53 (re)activation

Molecular Oncology, EarlyView.
Dimethyl fumarate (DMF) reduces growth of HPV‐positive cervical cancer spheroids and induces ferroptosis in cervical cancer cells via blocking SLC7A11/Glutathione (GSH) axis. Combination of subcytotoxic doses of DMF and cisplatin (CDDP) further suppresses spheroid growth and drives cell death in 2D culture models.
Carolina Punziano, Giuseppina Minopoli, Simona Romano, Laura Marrone, Katia Aquilano, Maria Lina Tornesello, Raffaella Faraonio   +6 more
wiley   +1 more source